StockData
Braveheart Bio, Inc. logo

Braveheart Bio, Inc. (BRVE) stock

BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.78−0.71 (-3.64%)

Close on Nov 17, 2026Market cap $1.69BP/E –Yield –

Braveheart Bio ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$30.15M–
Q3 FY2025Sep 30, 2025-$59.29M–

More Braveheart Bio figures

See a number that looks wrong?